

INTRODUCTION	XV
OBJECTIVES OF REVIEW	XV
AUDIENCE FOR REVIEW	XV
SCOPE AND CONTENT	XVI
METHODOLOGY AND INFORMATION SOURCES.....	XVI
ASSUMPTIONS	XVII
RELATED REPORTS	XVII
 EXECUTIVE SUMMARY	 XIX
SUMMARY TABLE GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS - 2000-2002 (\$ MILLIONS).....	 XIX
SUMMARY FIGURE GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS - 2000-2002 (\$ MILLIONS).....	 XX
 OVERVIEW	 1
DEFINITION OF BIOTECHNOLOGY.....	1
THE BACK BONE OF BIOTECHNOLOGY: CELLULAR AND BIOLOGICAL MOLECULES	1
WHAT ARE BIOLOGICS?.....	2
BIOTECHNOLOGY BASED DRUGS-UNDERSTANDING THE CONCEPT OF BIOLOGICS AND NEW CHEMICAL ENTITIES	3
BIOTECHNOLOGY INDUSTRY BACKGROUND.....	4
BENCHMARKING NUMBERS	4
ACCOMPLISHMENTS OF THE BIOTECHNOLOGY INDUSTRY.....	5
TABLE 1 BIOTECH DRUG/VACCINE/ NEW INDICATION FDA APPROVALS BY YEAR, 1995-2002.....	5
FIGURE 1 BIOTECH DRUG/VACCINE/ NEW INDICATION FDA APPROVALS BY YEAR, 1995-2002.....	6
BIOTECHNOLOGY'S CONTRIBUTION TO THE PHARMA INDUSTRY.....	6
BIOTECHNOLOGY INDUSTRY PROFILE.....	7
BIOTECHNOLOGY DERIVED DRUGS VS CONVENTIONAL CHEMICAL DRUGS	8
TABLE 2 CHEMICAL DRUGS VS BIOTECH DRUGS: A COMPARATIVE ANALYSIS OF CHARACTERISTICS.....	9
APPROVAL AGENCIES AND GOVERNMENT REGULATIONS	10
UNITED STATES	10
Center for Biological Evaluation and Research	10
EUROPE.....	10
European Agency for the Evaluation of Medicinal Products	10
United Kingdom	10
Medicines Control Agency (MCA)	10
Committee on Safety of Medicines (CSM)	11

FOCUS OF DRUG DISCOVERY IN BIOTECHNOLOGY	12
<i>TABLE 3 MAJOR BIOTECH HEALTHCARE PRODUCTS CATEGORIZED BY</i>	
<i>DISEASE TARGETS</i>	12
DRUG DISCOVERY PROCESS: OVERVIEW	12
<i>FIGURE 2 THE BIOTECHNOLOGY VALUE CHAIN: DISCOVERING A DRUG</i>	13
THERAPEUTIC TARGET	13
<i>FIGURE 3 FROM GENOME TO DRUG - IDENTIFYING THE THERAPEUTIC DRUG</i>	
TARGET.....	14
RESEARCH	14
PILOT-SCALE MANUFACTURING	15
PRECLINICAL STUDY	15
CLINICAL EVALUATION	15
Phase I: Safety	16
Phase II: Safety and Efficacy	16
Phase III: Controlled Safety and Efficacy	16
FDA Approval	16
Post Approval Monitoring	17
<i>TABLE 4 AVERAGE YEARS INVOLVED IN EACH STAGE OF DRUG DISCOVERY</i>	17
<i>FIGURE 4 DRUG DISCOVERY FACTS</i>	18
ENABLING TECHNOLOGIES	19
INTRODUCTION	19
BIOINFORMATICS.....	20
DEFINITION.....	20
IMPORTANCE.....	20
EVOLUTIONARY BIOLOGY	20
PROTEIN/MOLECULAR MODELING	21
GENOMICS.....	21
GENOME MAPPING.....	21
GENETIC MAPS.....	21
Genetic Markers	21
Linkage Analysis	22
Linkage Analysis in Patient Populations	22
PHYSICAL MAPPING.....	23
DNA MICROARRAYS.....	23
Promise of Microarrays in Treating Diseases	24
PROTEOMICS	24
PROTEIN STRUCTURE	24
PROTEIN CONFORMATION	25
DETERMINING PROTEIN STRUCTURE - CONVENTIONAL	
TECHNIQUES.....	25
X Ray Crystallography	25
Nuclear Magnetic Resonance (NMR) Spectroscopy	25
Determining Protein Structure - Advent Of	
Computational Modeling	26
DATABASES	26

Databases (Continued)	27
PHARMACOGENOMICS	28
PREDICTING DRUG RESPONSE: USE OF A PERSON'S GENETIC VARIATIONS	28
PHARMECOGENOMICS: PROMISE TO DRUG DEVELOPMENT AND TESTING	28
BIOTECHNOLOGY BASED PRODUCTS IN HEALTHCARE	29
OVERVIEW	29
THE BIG PICTURE OF BIOTECHNOLOGY DERIVED HEALTHCARE PRODUCTS - <i>IT ONLY GETS BIGGER!</i>	29
TABLE 5 FDA APPROVED BIOTECHNOLOGY DERIVED PRODUCTS IN MARKET	30
TABLE 5 (CONTINUED)	31
TABLE 5 (CONTINUED)	32
TABLE 5 (CONTINUED)	33
TABLE 5 (CONTINUED)	34
TABLE 5 (CONTINUED)	35
TABLE 5 (CONTINUED)	36
TABLE 6 BIOLOGICAL PRODUCTS APPROVED BY FDA 2000	37
TABLE 7 BIOLOGICAL PRODUCTS APPROVED BY FDA 2001	38
TABLE 7 (CONTINUED)	39
TABLE 8 BIOLOGICAL PRODUCTS APPROVED BY FDA 2002	40
TABLE 8 (CONTINUED)	41
FINANCIAL OVERVIEW OF BIOTECHNOLOGY IN HEALTHCARE	42
BIOTECH DERIVED PRODUCT SALES — PERFORMANCE SPEAKS FOR THE STARS	43
The Hatchlings Score a Goal	43
TABLE 9 INITIAL SALES OF PRODUCTS APPROVED IN 2001	43
Emerging Star Products	44
TABLE 10 PERFORMANCES OF THE EMERGING STARS: FIRST FULL-YEAR SALES VS. YEAR 2001 SALES (\$ MILLIONS)	44
The Stars Are Here to Stay	45
TABLE 11 STAR PRODUCTS: YEAR 2000 SALES VS. YEAR 2001 SALES (\$ MILLIONS)	45
MARKET SIZE	46
TABLE 12 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS, 2000-2002 (\$ MILLIONS)	46
BIOLOGICS	46
TABLE 13 GLOBAL MARKET FOR BIOLOGICS, 2000-2002 (\$ MILLIONS)	46
THERAPEUTIC PROTEINS	47
Introduction	47
Production	47
Production (Continued)	48
Production (Continued)	49
FIGURE 5 OVERVIEW OF THERAPEUTIC PROTEIN PRODUCTION PROCESS	50
Market Size	50

<i>TABLE 14 WORLDWIDE SALES OF THERAPEUTIC PROTEIN CATEGORIES, 2000-2002 (\$ MILLIONS)</i>	51
<i>FIGURE 6 WORLDWIDE SALES OF THERAPEUTIC PROTEIN CATEGORIES, 2000-2002 (\$ MILLIONS)</i>	52
Market Resistors.....	52
<i>TABLE 15 THERAPEUTIC PROTEINS BY TRADE NAME-IN MARKET</i>	53
<i>TABLE 15 (CONTINUED)</i>	54
<i>TABLE 15 (CONTINUED)</i>	55
<i>TABLE 15 (CONTINUED)</i>	56
<i>TABLE 15 (CONTINUED)</i>	57
Products	58
Erythropoietins	58
Definition	58
Market.....	58
<i>TABLE 16 WORLDWIDE SALES ERYTHROPOIETIN BASED BIOTECH DRUGS, 2000-2002 (\$ MILLIONS)</i>	58
Interferons.....	59
Definition	59
<i>TABLE 17 WORLDWIDE SALES OF INTERFERONS IN HEALTHCARE, 2000-2002 (\$ MILLIONS)</i>	60
Types	60
Products	61
Monoclonal Antibodies (MABs)	62
Introduction	62
Market Size.....	62
<i>TABLE 18 WORLDWIDE SALES OF MONOCLONAL ANTIBODY BASED BIOTECH DRUGS, 2000-2002 (\$ MILLIONS)</i>	63
Products	64
Insulins.....	65
Introduction	65
Market Size.....	65
<i>TABLE 19 WORLDWIDE SALES INSULIN BASED BIOTECH DRUGS, 2000-2002 (\$ MILLIONS)</i>	65
Products	66
Colony Stimulating Factors (CSFs)	66
Definition	66
Market Size.....	67
<i>TABLE 20 WORLDWIDE SALES FOR COLONY STIMULATING FACTOR BASED DRUGS IN HEALTHCARE, 2000-2002 (\$ MILLIONS)</i>	67
Products	67
Interleukins.....	68
Definition	68
<i>TABLE 21 WORLDWIDE SALES OF INTERLEUKINS IN HEALTHCARE, 2000-2002 (\$ MILLIONS)</i>	68
Types	69
Plasminogen Activators/Enzymes	70
<i>TABLE 22 WORLDWIDE SALES OF PLASMINOGEN ACTIVATORS IN HEALTHCARE, 2000-2002 (\$ MILLIONS)</i>	70

Products	71
Others.....	72
Blood Clotting Factors	73
Blood Function and Components.....	73
Blood-Related Disorders.....	74
Biotechnology Based Treatment of Blood Disorders	75
Blood Clotting Factors	75
<i>TABLE 23 WORLDWIDE SALES BLOOD CLOTTING FACTOR BASED BIOTECH DRUGS, 2000-2002 (\$ MILLIONS).....</i>	<i>75</i>
<i>TABLE 24 BIOTECHNOLOGY BASED THERAPIES FOR BLOOD DISORDERS.....</i>	<i>76</i>
<i>TABLE 24 (CONTINUED)</i>	<i>77</i>
FDA Regulations for Blood and Blood Components	77
Good Manufacturing Policies in Development of Blood and Blood Components.....	77
GENE THERAPY.....	78
Introduction	78
Frustrating Setbacks.....	78
<i>TABLE 25 SELECTED GENE THERAPY TRIALS.....</i>	<i>78</i>
<i>TABLE 25 (CONTINUED)</i>	<i>79</i>
<i>TABLE 25 (CONTINUED)</i>	<i>80</i>
Modest Successes.....	80
SCID and Gene Therapy	80
SCID and Gene Therapy (Continued).....	81
VACCINES	82
Facts about Vaccines	82
Conventional Vaccines.....	82
Recombinant DNA Vaccines.....	83
<i>TABLE 26 BIOTECHNOLOGY BASED VACCINES IN MARKET.....</i>	<i>84</i>
<i>TABLE 26 (CONTINUED)</i>	<i>85</i>
<i>TABLE 27 WORLDWIDE SALES OF BIOTECH BASED VACCINES IN HEALTHCARE, 2000-2002 (\$ MILLIONS).....</i>	<i>85</i>
Representative r-DNA Vaccines.....	86
DEVICES.....	87
Biosensors	87
Blood and HIV Testing Kits	87
<i>TABLE 28 BIOTECHNOLOGY BASED DEVICES IN MARKET.....</i>	<i>88</i>
<i>TABLE 28 (CONTINUED)</i>	<i>89</i>
<i>TABLE 28 (CONTINUED)</i>	<i>90</i>
<i>TABLE 28 (CONTINUED)</i>	<i>91</i>
ALLERGENICS.....	92
Introduction	92
New Biotechnological Approaches to the Treatment of Allergic Diseases	92
NEW CHEMICAL ENTITIES.....	93
NEW CHEMICAL ENTITIES vs. BIOTECHNOLOGY DRUGS	93

HISTORY OF NEW CHEMICAL ENTITIES	94
MARKET SIZE	94
TABLE 29 GLOBAL MARKET FOR NEW CHEMICAL ENTITIES, 2000-2002 (\$ MILLIONS).....	94
PRODUCTS	94
Products (Continued).....	95
TABLE 30 NEW CHEMICAL ENTITIES DEVELOPED BY BIOTECH & PHARMA COMPANIES: STAR PRODUCTS	96
TABLE 30 (CONTINUED)	97
TABLE 30 (CONTINUED)	98
TABLE 30 (CONTINUED)	99
TABLE 31 WORLDWIDE SALES OF NEW CHEMICAL ENTITIES, 2000-2002 (\$ MILLIONS).....	100
BIOTECHNOLOGY BASED PRODUCTS IN HEALTHCARE: MEETING THE NEEDS OF CHRONIC DISEASES	101
TABLE 32 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS BY DISEASE, 2000-2002 (\$ MILLIONS).....	101
AIDS	102
OVERVIEW	102
BIOTECH BASED TREATMENTS FOR AIDS	103
TABLE 33 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR AIDS, 2000-2002 (\$ MILLIONS).....	103
ANTIVIRALS	103
OVERVIEW	103
BIOTECH BASED TREATMENTS FOR VIRAL/FLU INFECTIONS.....	104
TABLE 34 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR VIRAL/FLU INFECTION, 2000-2002 (\$ MILLIONS).....	104
BLOOD DISORDERS	104
OVERVIEW	104
Hemophilia.....	104
Anemia	105
Thrombocytopenia	105
BIOTECH BASED TREATMENTS FOR BLOOD DISORDERS.....	105
TABLE 35 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR BLOOD DISORDERS, 2000-2002 (\$ MILLIONS)	106
CANCER.....	106
OVERVIEW	106
BIOTECH BASED TREATMENTS FOR CANCER.....	107
TABLE 36 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR CANCER, 2000-2002 (\$ MILLIONS)	107
CARDIO-VASCULAR DISEASES	107
OVERVIEW	107
Angina	107
Myocardial Infarction	108
Pulmonary Embolism	108
Transient Ischemic Attack	108

Ischemic Heart Disease.....	108
BIOTECHNOLOGY BASED TREATMENTS FOR CARDIO- VASCULAR DISEASES	108
TABLE 37 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR CARDIO-VASCULAR DISEASES, 2000-2002 (\$ MILLIONS).....	109
CENTRAL NERVOUS SYSTEM DISORDERS	109
OVERVIEW	109
BIOTECH BASED TREATMENTS FOR CNS DISORDERS	109
TABLE 38 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR CNS DISORDERS, 2000-2002 (\$ MILLIONS).....	110
DIABETES	110
OVERVIEW	110
Type 1 Diabetes Mellitus.....	110
Type 2 Diabetes Mellitus.....	110
Gestational Diabetes	110
BIOTECH BASED TREATMENTS FOR DIABETES.....	111
TABLE 39 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR DIABETES, 2000-2002 (\$ MILLIONS).....	111
INFECTIONS.....	111
OVERVIEW	111
BIOTECH BASED TREATMENTS FOR INFECTIONS	112
TABLE 40 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR INFECTIONS, 2000-2002 (\$ MILLIONS).....	112
INFLAMMATION.....	112
OVERVIEW	112
BIOTECH BASED TREATMENTS FOR INFLAMMATION	113
TABLE 41 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR INFLAMMATION, 2000-2002 (\$ MILLIONS).....	113
METABOLIC DISORDERS.....	113
OVERVIEW	113
Growth Hormone Disorder.....	114
Gaucher's Disease.....	114
BIOTECHNOLOGY BASED TREATMENTS FOR METABOLIC DISORDERS	114
TABLE 42 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR METABOLIC DISORDERS, 2000-2002 (\$ MILLIONS).....	114
OPHTHALMIC	114
TABLE 43 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR OPHTHALMIC DISORDERS, 2000-2002 (\$ MILLIONS).....	115
PULMONARY DISORDERS	115
OVERVIEW	115
Cystic Fibrosis	115
Respiratory Syncytial Virus.....	115
BIOTECHNOLOGY BASED TREATMENTS FOR PULMONARY DISORDERS.....	116
TABLE 44 GLOBAL MARKET FOR BIOTECH HEALTHCARE PRODUCTS FOR PULMONARY DISORDERS, 2000-2002 (\$ MILLIONS).....	116

GLOBAL BIOTECHNOLOGY INDUSTRY	117
INTRODUCTION	117
THE GLOBAL BIOTECH PIPELINE.....	117
OVERVIEW OF THE GLOBAL BIOTECH INDUSTRY	117
<i>TABLE 45 OVERVIEW OF THE GLOBAL BIOTECHNOLOGY INDUSTRY, 2001</i>	<i>118</i>
<i>TABLE 46 BENCHMARKING BIOTECHNOLOGY COMPANIES: FINANCIAL</i>	
<i>SNAPSHOT UPTO THIRD QUARTER, 2002.....</i>	<i>118</i>
<i>TABLE 46 (CONTINUED)</i>	<i>119</i>
U.S. BIOTECH INDUSTRY	119
IMPORTANCE OF THE U.S. BIOTECH INDUSTRY.....	119
KEY THERAPY AREAS	120
<i>TABLE 47 2002 PIPELINE OF SELECTED BIOTECHNOLOGY-DERIVED PRODUCTS</i>	
<i>IN THE U.S.....</i>	<i>120</i>
<i>TABLE 47 (CONTINUED)</i>	<i>121</i>
<i>TABLE 47 (CONTINUED)</i>	<i>122</i>
<i>TABLE 47 (CONTINUED)</i>	<i>123</i>
<i>TABLE 47 (CONTINUED)</i>	<i>124</i>
SELECTED U.S. BIOTECHNOLOGY COMPANIES: PIPELINE	
PROFILES.....	124
Selected U.S. Biotechnology Companies: Pipeline Profiles	
(Continued).....	125
Selected U.S. Biotechnology Companies: Pipeline Profiles	
(Continued).....	126
Selected U.S. Biotechnology Companies: Pipeline Profiles	
(Continued).....	127
Selected U.S. Biotechnology Companies: Pipeline Profiles	
(Continued).....	128
Selected U.S. Biotechnology Companies: Pipeline Profiles	
(Continued).....	129
EUROPE.....	130
INTRODUCTION.....	130
ATTRACTING VENTURE CAPITAL	130
<i>TABLE 48 PRODUCT PIPELINE OF EUROPEAN PUBLIC COMPANIES.....</i>	<i>131</i>
<i>FIGURE 7 PRODUCT PIPELINE OF EUROPEAN PUBLIC COMPANIES</i>	<i>132</i>
GEOGRAPHIC SPAN	132
The United Kingdom	132
<i>TABLE 49 SELECTED EUROPEAN PRODUCTS IN PHASE III OF PIPELINE.....</i>	<i>133</i>
The Netherlands	133
CANADA	134
<i>TABLE 50 TOP 20 CANADIAN BIOTECH COMPANIES RANKED BY MARKET CAP (\$</i>	
<i>MILLIONS).....</i>	<i>134</i>
<i>TABLE 50 (CONTINUED)</i>	<i>135</i>
ASIA/PACIFIC	135
AUSTRALIA.....	135
INDIA	135
CHINA	136
TAIWAN	137

MERGERS AND CORPORATE DEALS: DO THEY PAY OFF?.....	138
<i>TABLE 51 2002 SALES OF BIOTECH BIOLOGICS PARTNERED IN PRECLINICAL STAGES</i>	138
<i>TABLE 52 2002 SALES OF NCEs PARTNERED IN PRECLINICAL STAGES</i>	139
<i>TABLE 53 2002 SALES OF BIOTECH BIOLOGICS WITH PHASE II PARTNERSHIPS</i>	140
<i>TABLE 54 2002 SALES OF NCEs BIOTECH DRUGS WITH PHASE II PARTNERSHIPS</i>	140
<i>TABLE 55 2002 SALES OF UNPARTNERED BIOTECH BIOLOGICS</i>	140
<i>TABLE 56 2002 SALES OF UNPARTNERED NCEs</i>	141

COMPANY PROFILES	142
ABBOTT	142
ABGENIX	142
ALLOS	142
AMERSHAM	143
AMGEN	143
AMYLIN	143
APPLERA	144
ASTRA ZENECA	144
BIOGEN	145
CELERA GENOMICS	145
CELGENE CORPORATION	146
CHIRON	146
CUBIST	146
CV THERAPEUTICS	147
ELI LILLY	147
GENENTECH	147
GENZYME	148
GILEAD SCIENCES	148
GLAXOSMITHKLINE	148
HUMAN GENOME SCIENCES	149
IDEC	149
IMMUNEX	149
INVITROGEN	150
ISIS	150
JOHNSON & JOHNSON	150
LA JOLLA	151
MEDIMMUNE	151
MERCK	152
MYRIAD GENETICS	152
NOVARTIS	153
ORA PHARMA	153
OSI	154
PFIZER	154
PHARMACIA	154

POWDERJECT	155
QLT INC	155
SERONO	155
TEXAS BIOTECHNOLOGY.....	156
VICAL.....	156
XOMA	156